Erlotinib (OSI-774), an FDA-approved epidermal growth factor receptor (EGFR) inhibitor, is extensively used in treating non-small cell lung cancer (NSCLC) and other malignancies. This study explores erlotinib's chemical instability under various stress conditions, including hydrolytic, oxidation, thermal, and photolytic stress, as well as its environmental impact due to drug residues in effluents. A stability-indicating reverse-phase liquid chromatography (RP-LC) method was developed to quantify erlotinib and its degradation products in pharmaceutical formulations. Gamma irradiation, an advanced oxidation process, was evaluated for its efficacy in degrading erlotinib in aqueous solutions. The study revealed a significant increase in degradation efficiency with higher absorbed doses and acidic pH conditions. These findings underscore the potential of gamma irradiation as an effective environmental remediation strategy for removing pharmaceutical contaminants and provide the first investigation of erlotinib's degradation via gamma irradiation
Ayşe Özdemir, Senem Şanlı, Meryem Cansu Şahin
You can use below filter to find your desired issue